Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice
- 20 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Sleep
- Vol. 44 (8)
- https://doi.org/10.1093/sleep/zsab043
Abstract
Orexins/hypocretins are hypothalamic neuropeptides that promote and stabilize wakefulness by binding to the orexin receptor type-1 (OX1R) and type-2 (OX2R). Disruption of orexinergic signaling results in the sleep disorder narcolepsy in mice, rats, dogs, and humans. The orexin receptor antagonist suvorexant promotes sleep by blocking both OX1R and OX2R. Whereas suvorexant has been clinically approved for the treatment of insomnia because it is well tolerated in experimental animals as well as in human patients, a logical question remains as to why orexin receptor antagonists do not induce overt narcolepsy-like symptoms. Here we show that acute and chronic suvorexant promotes both rapid eye movement (REM) and non-REM (NREM) sleep without inducing cataplexy in mice. Interestingly, chronic suvorexant increases OX2R mRNA and decreases orexin mRNA and peptide levels, which remain low long after termination of suvorexant administration. When mice are chronically treated with suvorexant and then re-challenged with the antagonist after a 1-week washout, however, cataplexy and sleep-onset REM (SOREM) are observed, which are exacerbated by chocolate administration. Heterozygous orexin knockout mice, with lower brain orexin levels, show cataplexy and SOREM after acute suvorexant administration. Furthermore, we find that acute suvorexant can induce cataplexy and SOREM in wild-type mice when co-administered with chocolate under stress-free (temporally anesthetized) conditions. Taken together, these results suggest that suvorexant can inhibit orexin synthesis resulting in susceptibility to narcolepsy-like symptoms in mice under certain conditions.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (17H06095, 16H01881)
- CREST (A3A28043)
- Uehara Memorial Foundation
- Takeda Science Foundation
This publication has 60 references indexed in Scilit:
- The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy thresholdBMC Neuroscience, 2013
- Amygdala Lesions Reduce Cataplexy in Orexin Knock-Out MiceJournal of Neuroscience, 2013
- Role of the Medial Prefrontal Cortex in CataplexyJournal of Neuroscience, 2013
- Differential Roles of Orexin Receptors in the Regulation of Sleep/WakefulnessFrontiers in Endocrinology, 2013
- The Dual Orexin Receptor Antagonist Almorexant Induces Sleep and Decreases Orexin-Induced Locomotion by Blocking Orexin 2 ReceptorsSleep, 2012
- Predictors of Hypocretin (Orexin) Deficiency in Narcolepsy Without CataplexySleep, 2012
- Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical TrialClinical Pharmacology & Therapeutics, 2012
- Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomniaNeuropharmacology, 2012
- Feeding-elicited cataplexy in orexin knockout miceNeuroscience, 2009
- Expression of a Poly-Glutamine-Ataxin-3 Transgene in Orexin Neurons Induces Narcolepsy–Cataplexy in the RatJournal of Neuroscience, 2004